Daniel C Berwick

List of Publications by Year
in descending order

21 papers	1,433 citations	567281 15 h-index	752698 20 g-index
21 all docs	21 docs citations	21 times ranked	2213 citing authors

#	Article	IF	Citations
1	The Identification of ATP-citrate Lyase as a Protein Kinase B (Akt) Substrate in Primary Adipocytes. Journal of Biological Chemistry, 2002, 277, 33895-33900.	3.4	312
2	Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles. Journal of Cell Science, 2004, 117, 5985-5993.	2.0	125
3	A Direct Interaction between Leucine-rich Repeat Kinase 2 and Specific Î²-Tubulin Isoforms Regulates Tubulin Acetylation. Journal of Biological Chemistry, 2014, 289, 895-908.	3.4	119
4	The importance of Wnt signalling for neurodegeneration in Parkinson's disease. Biochemical Society Transactions, 2012, 40, 1123-1128.	3.4	115
5	Role of protein kinase B in insulin-regulated glucose uptake. Biochemical Society Transactions, 2005, 33, 346-349.	3.4	110
6	LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. Molecular Neurodegeneration, 2019, 14, 49.	10.8	106
7	LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Human Molecular Genetics, 2012, 21, 4966-4979.	2.9	90
8	LRRK2 signaling pathways: the key to unlocking neurodegeneration?. Trends in Cell Biology, 2011, 21, 257-265.	7.9	73
9	The regulation and deregulation of Wnt signaling by PARK genes in health and disease. Journal of Molecular Cell Biology, 2014, 6, 3-12.	3.3	69
10	Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity. Frontiers in Molecular Neuroscience, 2016, 9, 18.	2.9	55
11	Identifying protein kinase substrates: hunting for the organ-grinder's monkeys. Trends in Biochemical Sciences, 2004, 29, 227-232.	7.5	47
12	Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of Î²-catenin signaling. Molecular Neurodegeneration, 2017, 12, 9.	10.8	45
13	The relevance of Î±-KLOTHO to the central nervous system: Some key questions. Ageing Research Reviews, 2017, 36, 137-148.	10.9	44
14	The development of inhibitors of leucineâ€rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play. British Journal of Pharmacology, 2022, 179, 1478-1495.	5.4	34
15	LRRK2: an Ã©minence grise of Wnt-mediated neurogenesis?. Frontiers in Cellular Neuroscience, 2013, 7, 82.	3.7	26
16	Downregulated Wnt/Î²-catenin signalling in the Down syndrome hippocampus. Scientific Reports, 2019, 9, 7322.	3.3	20
17	Regulation Of Brn-3a N-terminal transcriptional activity by MEK1/2-ERK1/2 signalling in neural differentiation. Brain Research, 2009, 1256, 8-18.	2.2	15
18	L'RRK de Triomphe: a solution for LRRK2 GTPase activity?. Biochemical Society Transactions, 2016, 44, 1625-1634.	3.4	15

#	Article	IF	Citations
19	A Simple Technique for the Prediction of Interacting Proteins Reveals a Direct Brn-3a-Androgen Receptor Interaction. Journal of Biological Chemistry, 2010, 285, 15286-15295.	3.4	10
20	Building Bridges In Neuropharmacology: New therapeutic approaches for psychiatric and neurodegenerative disorders. British Journal of Pharmacology, 2022, 179, 1475-1477.	5.4	3
21	PI3K, PTEN and Akt. , 2005, , 239-257.		0